UA96447C2 - Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы - Google Patents
Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системыInfo
- Publication number
- UA96447C2 UA96447C2 UAA200814135A UAA200814135A UA96447C2 UA 96447 C2 UA96447 C2 UA 96447C2 UA A200814135 A UAA200814135 A UA A200814135A UA A200814135 A UAA200814135 A UA A200814135A UA 96447 C2 UA96447 C2 UA 96447C2
- Authority
- UA
- Ukraine
- Prior art keywords
- penten
- amine
- methyl
- nervous system
- central nervous
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title abstract 2
- HSAWPCNJLDNOEM-UHFFFAOYSA-N 3-propan-2-yloxypyridine Chemical compound CC(C)OC1=CC=CN=C1 HSAWPCNJLDNOEM-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74682106P | 2006-05-09 | 2006-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA96447C2 true UA96447C2 (ru) | 2011-11-10 |
Family
ID=38441430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200814135A UA96447C2 (ru) | 2006-05-09 | 2007-08-05 | Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8461344B2 (enExample) |
| EP (2) | EP2418201B1 (enExample) |
| JP (1) | JP4477097B2 (enExample) |
| KR (1) | KR20090005369A (enExample) |
| CN (1) | CN101472893A (enExample) |
| AR (1) | AR060786A1 (enExample) |
| AU (1) | AU2007249485B2 (enExample) |
| BR (1) | BRPI0709781A2 (enExample) |
| CA (1) | CA2649961A1 (enExample) |
| DK (1) | DK2418201T3 (enExample) |
| EC (1) | ECSP088876A (enExample) |
| ES (1) | ES2460919T3 (enExample) |
| HR (1) | HRP20140385T1 (enExample) |
| IL (1) | IL194833A0 (enExample) |
| MX (1) | MX2008013982A (enExample) |
| MY (1) | MY144132A (enExample) |
| NO (1) | NO20084567L (enExample) |
| NZ (1) | NZ597177A (enExample) |
| PL (1) | PL2418201T3 (enExample) |
| PT (1) | PT2418201E (enExample) |
| RS (1) | RS53286B (enExample) |
| RU (1) | RU2440984C2 (enExample) |
| SA (1) | SA07280230B1 (enExample) |
| SI (1) | SI2418201T1 (enExample) |
| TW (1) | TWI389889B (enExample) |
| UA (1) | UA96447C2 (enExample) |
| UY (1) | UY30330A1 (enExample) |
| WO (1) | WO2007134034A1 (enExample) |
| ZA (1) | ZA200809284B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| WO2007134038A2 (en) * | 2006-05-09 | 2007-11-22 | Astrazeneca Ab | Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
| TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| WO2008034041A2 (en) * | 2006-09-15 | 2008-03-20 | Astrazeneca Ab | Therapeutic combinations |
| US20100028447A1 (en) * | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
| KR20100052490A (ko) * | 2007-07-31 | 2010-05-19 | 타가셉트 인코포레이티드 | (2ｓ)-(4ｅ)-ｎ-메틸-5-(3-(5-이소프로폭시피리딘)일)-4-펜텐-2-아민의 경피투여 |
| CN102065845A (zh) * | 2008-06-11 | 2011-05-18 | 阿斯利康(瑞典)有限公司 | 含有(2s)-(4e)-n-甲基-5-(5-异丙氧基吡啶-3-基)-戊-4-烯-2-胺的舌下组合物 |
| WO2010080757A2 (en) * | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
| FR2959107B1 (fr) | 2010-04-23 | 2015-03-27 | Oreal | Unite d'application d'un produit cosmetique |
| JP2013528601A (ja) * | 2010-05-20 | 2013-07-11 | アストラゼネカ・アクチエボラーグ | アリール置換オレフィン系アミンの新規な製造方法 |
| WO2013184732A1 (en) * | 2012-06-06 | 2013-12-12 | Targacept, Inc. | Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate |
| KR101579904B1 (ko) | 2014-09-05 | 2016-01-05 | 동신대학교산학협력단 | 마스카라 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4192946A (en) * | 1978-06-29 | 1980-03-11 | Ciba-Geigy Corporation | Process for producing 3-hydroxy-5-halopyridines |
| DE3148651A1 (de) * | 1981-12-09 | 1983-07-21 | Henkel Kgaa | "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente" |
| US4582823A (en) * | 1984-08-15 | 1986-04-15 | Warner-Lambert Company | Method for treating schizophrenia and medicaments therefor |
| WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
| IT1226727B (it) * | 1988-07-29 | 1991-02-05 | Simes | Farmaci precursori della dopamina. |
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| ES2070994T3 (es) * | 1989-04-20 | 1995-06-16 | Zambon Spa | Profarmaco de dopamina. |
| US5187166A (en) * | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
| AU9171791A (en) | 1990-12-27 | 1992-08-17 | Abbott Laboratories | N-protected aminoalkylaldehydes |
| DE69213559T2 (de) | 1991-05-30 | 1997-02-27 | Mitsui Toatsu Chemicals | Tetravinylpyrazine-Verbindung, Verfahren zur Herstellung derselben und elektrolumineszentes Element und damit hergesteller nichtlinearer optischer Stoff |
| US5212188A (en) * | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| IT1274018B (it) * | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
| EP0765320B1 (en) | 1994-06-14 | 2001-10-10 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| US5604231A (en) * | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| AT403803B (de) * | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US6979695B2 (en) | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US20020052497A1 (en) * | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| DE69739142D1 (de) | 1996-04-23 | 2009-01-15 | Targacept Inc | Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| US5811442A (en) * | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| PT983249E (pt) | 1997-05-08 | 2002-08-30 | Pfizer Prod Inc | Procesos e intermediarios para a preparacao de derivados de indazole substituidos |
| ATE278670T1 (de) | 1997-10-27 | 2004-10-15 | Neurosearch As | Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren |
| US6632823B1 (en) * | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| DE69919537T2 (de) | 1998-06-16 | 2005-09-08 | Targacept, Inc. | Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten |
| US6232316B1 (en) * | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| US6337351B1 (en) * | 1998-10-22 | 2002-01-08 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| WO2000075110A1 (en) | 1999-06-07 | 2000-12-14 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| GB9922271D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
| US6506769B2 (en) * | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| PL358375A1 (en) | 2000-04-13 | 2004-08-09 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| US6432954B1 (en) * | 2000-07-14 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6743812B1 (en) * | 2000-07-14 | 2004-06-01 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| CN1610547A (zh) | 2001-03-29 | 2005-04-27 | 伊莱利利公司 | 用作5－ht6受体拮抗剂的n－(2－芳乙基)苄胺 |
| GB2381750A (en) * | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
| BR0214929A (pt) | 2001-12-14 | 2006-05-30 | Targacept Inc | métodos e composições para o tratamento de distúrbios do sistema nervoso central |
| WO2003082205A2 (en) | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Compounds and methods |
| US20040044023A1 (en) * | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
| US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| EP1699488A2 (en) | 2003-12-23 | 2006-09-13 | Pfizer Products Incorporated | Therapeutic combination for cognition enhancement and psychotic disorders |
| US20050171088A1 (en) | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| WO2005105729A1 (en) | 2004-02-13 | 2005-11-10 | Mediquest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
| WO2006015299A2 (en) * | 2004-07-30 | 2006-02-09 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
| JP4148199B2 (ja) | 2004-07-30 | 2008-09-10 | 松下電工株式会社 | 電気かみそり |
| US7780981B2 (en) * | 2004-09-13 | 2010-08-24 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US7459469B2 (en) * | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
| UA88792C2 (ru) | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
| WO2007134038A2 (en) | 2006-05-09 | 2007-11-22 | Astrazeneca Ab | Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
| TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型 |
| US20080138416A1 (en) | 2006-06-13 | 2008-06-12 | Fmc Biopolymer As | Method and systems for using biopolymer-based beads and hydrogels |
| WO2008034041A2 (en) | 2006-09-15 | 2008-03-20 | Astrazeneca Ab | Therapeutic combinations |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US20100028447A1 (en) | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
-
2007
- 2007-04-27 TW TW096115162A patent/TWI389889B/zh not_active IP Right Cessation
- 2007-05-07 UY UY30330A patent/UY30330A1/es not_active Application Discontinuation
- 2007-05-07 AR ARP070101972A patent/AR060786A1/es not_active Application Discontinuation
- 2007-05-08 SI SI200731433T patent/SI2418201T1/sl unknown
- 2007-05-08 AU AU2007249485A patent/AU2007249485B2/en not_active Ceased
- 2007-05-08 NZ NZ597177A patent/NZ597177A/xx not_active IP Right Cessation
- 2007-05-08 ES ES11167528.6T patent/ES2460919T3/es active Active
- 2007-05-08 JP JP2009503340A patent/JP4477097B2/ja not_active Expired - Fee Related
- 2007-05-08 EP EP11167528.6A patent/EP2418201B1/en active Active
- 2007-05-08 MX MX2008013982A patent/MX2008013982A/es active IP Right Grant
- 2007-05-08 BR BRPI0709781-6A patent/BRPI0709781A2/pt not_active IP Right Cessation
- 2007-05-08 RS RS20140212A patent/RS53286B/sr unknown
- 2007-05-08 EP EP07783431A patent/EP2021326A1/en not_active Withdrawn
- 2007-05-08 DK DK11167528.6T patent/DK2418201T3/da active
- 2007-05-08 CA CA002649961A patent/CA2649961A1/en not_active Abandoned
- 2007-05-08 US US11/745,682 patent/US8461344B2/en not_active Expired - Fee Related
- 2007-05-08 KR KR1020087027218A patent/KR20090005369A/ko not_active Abandoned
- 2007-05-08 SA SA07280230A patent/SA07280230B1/ar unknown
- 2007-05-08 WO PCT/US2007/068446 patent/WO2007134034A1/en not_active Ceased
- 2007-05-08 PL PL11167528T patent/PL2418201T3/pl unknown
- 2007-05-08 MY MYPI20084443A patent/MY144132A/en unknown
- 2007-05-08 CN CNA2007800168072A patent/CN101472893A/zh active Pending
- 2007-05-08 PT PT111675286T patent/PT2418201E/pt unknown
- 2007-05-08 RU RU2008148325/04A patent/RU2440984C2/ru not_active IP Right Cessation
- 2007-08-05 UA UAA200814135A patent/UA96447C2/ru unknown
-
2008
- 2008-10-22 IL IL194833A patent/IL194833A0/en unknown
- 2008-10-29 ZA ZA200809284A patent/ZA200809284B/xx unknown
- 2008-10-30 NO NO20084567A patent/NO20084567L/no not_active Application Discontinuation
- 2008-11-07 EC EC2008008876A patent/ECSP088876A/es unknown
-
2009
- 2009-10-29 US US12/608,450 patent/US20100048643A1/en not_active Abandoned
-
2013
- 2013-05-14 US US13/893,408 patent/US20130310425A1/en not_active Abandoned
-
2014
- 2014-04-28 HR HRP20140385TT patent/HRP20140385T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA96447C2 (ru) | Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы | |
| EP2217596B8 (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
| MY149855A (en) | Benzimidazole derivatives and their use for modulating the gaba? receptor complex | |
| TN2011000437A1 (en) | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | |
| TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
| MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
| MY150285A (en) | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | |
| WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| MX2010004494A (es) | Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios. | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| MY156822A (en) | Indole derivatives as s1p1 receptor agonists | |
| WO2008130320A3 (en) | Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | |
| EA201000365A1 (ru) | Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза | |
| PL1979355T3 (pl) | Pochodne spiro imidazoli jako modulatory PPAR | |
| WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
| JO2645B1 (en) | Vehicles | |
| WO2009025785A3 (en) | Cb2 receptor ligands for the treatment of pain | |
| TW200602330A (en) | Compounds and compositions as PPAR modulators | |
| TW200611695A (en) | Pyrrolopyridine derivatives | |
| TN2009000014A1 (en) | Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same | |
| IL189974A0 (en) | Benzimidazole derivatives and their use for modulating the gabaa receptor complex | |
| WO2011060253A3 (en) | Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms | |
| GB0611907D0 (en) | Compounds | |
| WO2008130319A3 (en) | Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain |